Diagnosis and Management of Gastrointestinal Manifestations in Children with Cystic Fibrosis

Author:

Anton-Păduraru Dana-Teodora12ORCID,Murgu Alina Mariela12,Bozomitu Laura Iulia12,Mîndru Dana Elena12,Iliescu Halițchi Codruța Olimpiada1,Trofin Felicia3ORCID,Ciongradi Carmen Iulia24ORCID,Sârbu Ioan24ORCID,Eṣanu Irina Mihaela5,Azoicăi Alice Nicoleta12

Affiliation:

1. Department of Mother and Child Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaṣi, Romania

2. “Sf. Maria” Children Emergency Hospital, 700309 Iasi, Romania

3. Department of Preventive Medicine and Interdisciplinarity–Microbiology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaṣi, Romania

4. 2nd Department of Surgery, Pediatric Surgery and Orthopedics, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaṣi, Romania

5. Medical Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iaṣi, Romania

Abstract

Cystic fibrosis (CF) is primarily known for its pulmonary consequences, which are extensively explored in the existing literature. However, it is noteworthy that individuals with CF commonly display gastrointestinal (G-I) manifestations due to the substantial presence of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in the intestinal tract. Recognized as pivotal nonpulmonary aspects of CF, G-I manifestations exhibit a diverse spectrum. Identifying and effectively managing these manifestations are crucial for sustaining health and influencing the overall quality of life for CF patients. This review aims to synthesize existing knowledge, providing a comprehensive overview of the G-I manifestations associated with CF. Each specific G-I manifestation, along with the diagnostic methodologies and therapeutic approaches, is delineated, encompassing the impact of innovative treatments targeting the fundamental effects of CF on the G-I tract. The findings underscore the imperative for prompt diagnosis and meticulous management of G-I manifestations, necessitating a multidisciplinary team approach for optimal care and enhancement of the quality of life for affected individuals. In conclusion, the authors emphasize the urgency for further clinical studies to establish a more robust evidence base for managing G-I symptoms within the context of this chronic disease. Such endeavors are deemed essential for advancing understanding and refining the clinical care of CF patients with G-I manifestations.

Publisher

MDPI AG

Subject

Clinical Biochemistry

Reference148 articles.

1. Cystic Fibrosis in the Intestine and the Influence on Digestion;J. Imunol. Sci.,2020

2. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota;Fiorotto;Cell. Mol. Gastroenterol. Hepatol.,2019

3. Betapudi, B., Aleem, A., and Kothadia, J.P. (2023). Cystic Fibrosis and Liver Disease, Stat Pearls Publishing.

4. Miron, I. (2016). PEDIATRIE, “Gr.T. Popa”, UMF.

5. From CFTR biology toward combinatorial pharmacothetarpy: Expanded classification of cystic fibrosis mutations;Veit;Mol. Biol. Cell,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3